America Latina Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on America Latina Times.

Press releases published on October 16, 2026

Oct. 16, 2026

可靈AI新一代模型Kling 4.0正式上線  專業影像模型「捲」出新高度

Indeterminate GlobeNewswire

Oct. 16, 2026

Quantisophy™ Opens Free Community Grid and 44 Ability Training Courses

Indeterminate EIN Presswire

Oct. 16, 2026

ANTIGUA AND BARBUDA NAMED WORLD’S BEST EMERGING CULINARY CITY DESTINATION 2026

Indeterminate EIN Presswire

Oct. 16, 2026

La tecnología impulsa el futuro de los viajes: JETOUR continúa expandiendo su ecosistema 'Travel+'

Indeterminate EIN Presswire

Oct. 16, 2026

GeoPark Announces Proposed Offering of Senior Notes

Indeterminate GlobeNewswire

Oct. 16, 2026

GeoPark Announces Commencement of Cash Tender Offer for Any and All of Its Outstanding 8.750% Senior Notes Due 2030

Indeterminate GlobeNewswire

Oct. 16, 2026

Exiro Nickel Completes Acquisition of Thompson Operations, Launches New Chapter for Northern Manitoba Mining

Indeterminate GlobeNewswire

Oct. 16, 2026

NeOnc’s Boldest Test Yet: Child’s Early Improvement Puts NEO100 in the Spotlight with Compassionate-Use Milestone

Indeterminate GlobeNewswire

Oct. 16, 2026

Aprea Therapeutics to Host Pre-ESMO Virtual Panel on the State of WEE1 Inhibition in Precision Oncology

Indeterminate GlobeNewswire

Oct. 16, 2026

Bitget Lists NeoSoul (DNA) for Spot Trading

Indeterminate GlobeNewswire

Oct. 16, 2026

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

Oct. 16, 2026

Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026

Indeterminate GlobeNewswire

Oct. 16, 2026

Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis

Indeterminate GlobeNewswire

Oct. 16, 2026

San Lorenzo Announces Private Placement of Up to $40 Million

Indeterminate GlobeNewswire

Oct. 16, 2026

Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Enrolls First Patient in Phase Ib/II Combination Trial in Metastatic Colorectal Cancer

Indeterminate GlobeNewswire

Oct. 16, 2026

Paladin Announces Availability of Notice of Meeting for Annual General Meeting

Indeterminate GlobeNewswire